Complete Blood Count — Routine blood cell profile

A complete blood count is an automated laboratory analysis that quantifies the three major populations of cells circulating in peripheral blood: erythrocytes (red blood cells), leukocytes (white blood cells), and thrombocytes (platelets). The assay measures absolute cell numbers, relative proportions, cell sizes, and related parameters, including haemoglobin concentration and haematocrit.

In addition to general counts, modern CBC analyses typically include a white blood cell differential. This sub-analysis details the exact quantities of individual leukocyte subtypes, such as neutrophils, lymphocytes, monocytes, eosinophils, and basophils. By assessing these measurements against established reference intervals, clinicians can detect bone marrow suppression, systemic inflammation, or haematological abnormalities.

During cancer care, bone marrow function is vulnerable to chemotherapy, radiation, and haematological malignancies. Monitoring blood counts alerts doctors to dangerous complications before severe symptoms arise. A low neutrophil count (neutropenia) increases vulnerability to life-threatening infections, low red cells cause severe fatigue, and low platelets raise bleeding risks. Keeping track of these numbers ensures treatments are paused, modified, or supported with medications safely.

A CBC requires a standard venepuncture blood sample, typically collected in a tube containing an anticoagulant like EDTA. While the CBC itself is not a genetic biomarker, it measures critical parameters such as the absolute neutrophil count (ANC). Results are often interpreted alongside peripheral blood smears, reticulocyte counts, iron studies, and bone marrow aspirate biopsies when abnormalities persist.

A complete blood count is essential across virtually all cancer types. It is particularly crucial in leukemias, lymphomas, and myelodysplastic syndromes, where blood cells themselves are malignant. It is equally important for solid tumour cancers—such as breast, bowel, lung, and prostate cancers—whenever patients undergo systemic cytotoxic chemotherapy or extensive radiotherapy.

If counts fall below safe thresholds, planned chemotherapy cycles may be postponed or reduced in dosage. Clinicians may prescribe supportive medications, such as granulocyte colony-stimulating factors (G-CSF) to boost white blood cells, erythropoietin-stimulating agents to support red cells, or arrange blood and platelet transfusions to maintain safe physiological levels.